Drug Sponsors Challenged to Contain Health Care Costs While Boosting Productivity, According to Tufts Center for the Study of Drug Development
January 08, 2015 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 8, 2015) - Drug developers will implement strategies over the next year to improve clinical study performance to help control R&D costs and boost overall...
Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion, According to the Tufts Center for the Study of Drug Development
November 18, 2014 10:30 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 18, 2014) - Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million,...
ADVISORY - Tufts CSDD to Disclose Cost of Developing a New Drug at Nov. 18 Briefing
November 10, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 10, 2014) -
FROM:
Tufts Center for the Study of Drug Development, Tufts University, Boston, Mass.
WHAT:
Press briefing at which Tufts...
CNS Drugs Take Longer to Develop and Have Lower Success Rates Than Other Drugs, According to the Tufts Center for the Study of Drug Development
November 04, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 4, 2014) - Drugs that treat central nervous system (CNS) diseases take more than a year longer to develop and are less than half as likely to obtain marketing...
Drug Companies Outline Ways Strategic Partnerships Can Boost Innovation, Tufts Center for the Study of Drug Development Reports
October 09, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 9, 2014) - Strategic relationships between drug developers and contract research organizations (CROs) are generating innovative approaches to clinical trial design...
Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
September 09, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
August 07, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
July 10, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
May 08, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
Drug Developers Are Using New Models and Methods to Boost Clinical Success Rates, According to Tufts Center for the Study of Drug Development
April 15, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 15, 2014) - Drug companies and their development partners who are seeking to increase clinical success rates of new drug candidates are developing tools to help them...